{"organizations": [], "uuid": "4905d61e7f5ff0e2bb0280c0827c44bde718c375", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-zynerba-pharmaceuticals-reports-q4/brief-zynerba-pharmaceuticals-reports-q4-loss-per-share-0-60-idUSASC09RPX", "country": "US", "domain_rank": 408, "title": "BRIEF-Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T12:57:00.000+02:00", "replies_count": 0, "uuid": "4905d61e7f5ff0e2bb0280c0827c44bde718c375"}, "author": "", "url": "https://www.reuters.com/article/brief-zynerba-pharmaceuticals-reports-q4/brief-zynerba-pharmaceuticals-reports-q4-loss-per-share-0-60-idUSASC09RPX", "ord_in_thread": 0, "title": "BRIEF-Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "zynerba pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 12, 2018 / 11:00 AM / in 7 minutes BRIEF-Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60 Reuters Staff March 12 (Reuters) - Zynerba Pharmaceuticals Inc: * ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS * Q4 LOSS PER SHARE $0.60 * Q4 EARNINGS PER SHARE VIEW $-0.60 — THOMSON REUTERS I/B/E/S * ‍EXPECTS TO INITIATE STUDY MID-YEAR 2018 TO SUPPORT AN NDA FOR ZYN002 IN FXS​ * ZYNERBA PHARMACEUTICALS - BELIEVES ‍CASH,CASH EQUIVALENT POSITION AS OF DEC 31, 2017 IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS WELL INTO 2019​ * ZYNERBA - BELIEVES CASH, CASH EQUIVALENT POSITION OF $62.5 MILLION AS OF DEC 31, 2017 SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS WELL INTO 2019 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-12T12:57:00.000+02:00", "crawled": "2018-03-12T13:13:42.005+02:00", "highlightTitle": ""}